This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CASI Pharmaceuticals, Inc.
Drug Names(s): ENMD0995, ENMD 0995
Description: ENMD 0995 is the S-enantiomer 3-amino derivative of thalidomide. Some animal studies suggest that it may be more active than thalidomide, and may also suppress activation of B cells.
Deal Structure: In 1998, when EntreMed was conducting Phase II oncology trials with thalidomide, EntreMed licensed thalidomide to Celgene for angiogenesis-related uses only. All thalidomide analogs, including ENMD 0995, were excluded from that 1998 license agreement.
EntreMed licensed ENMD0995 and other thalidomide analogs to Celgene on January 2, 2003.
EntreMed and CASI
In June 2014, EntreMed announced that at its annual meeting of stockholders, stockholders voted in favor of changing the companys corporate name to CASI Pharmaceuticals, Inc.
Partners: Celgene Corporation
Additional information available to subscribers only: